Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
March 12 2025 - 10:51AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March
2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
12
March 2025 - “Director/PDMR Shareholding”
|
99.1
Haleon plc: Director/PDMR
Shareholding
12 March 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by
Persons Discharging Managerial Responsibilities
("PDMRs").
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Adrian
Morris
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
General
Counsel - PDMR
|
|
b)
|
Initial notification /Amendment
|
Initial
Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Haleon
plc
|
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary
Shares of £0.01 each
|
|
|
|
|
Identification
code
|
GB00BMX86B70
|
|
|
|
b)
|
Nature of the transaction
|
Acquisition
of Partnership Shares and award of Matching Shares under the
Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£4.005
|
31
|
|
|
|
|
£Nil
|
31
(Matching Shares)
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
62
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
11 March 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Tamara
Rogers
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief
Marketing Officer - PDMR
|
|
b)
|
Initial notification /Amendment
|
Initial
Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Haleon
plc
|
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of £0.01 each
|
|
|
|
|
Identification
code
|
GB00BMX86B70
|
|
|
|
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares
under the Company's Share Reward Plan
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£4.005
|
31
|
|
|
|
|
£Nil
|
31
(Matching Shares)
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
62
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
11 March 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date: March 12,
2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (NYSE:HLN)
Historical Stock Chart
From Feb 2025 to Mar 2025
Haleon (NYSE:HLN)
Historical Stock Chart
From Mar 2024 to Mar 2025
